MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

MicroRNAs (miRNA) have rapidly emerged as modulators of gene expression in cancer in which they may have great diagnostic and therapeutic import. MicroRNA-199a-3p (miR-199a-3p) is downregulated in several human malignancies including hepatocellular carcinoma (HCC). Here, we show that miR-199a-3p targets mammalian target of rapamycin (mTOR) and c-Met in HCC cells. Restoring attenuated levels of miR-199a-3p in HCC cells led to G(1)-phase cell cycle arrest, reduced invasive capability, enhanced susceptibility to hypoxia, and increased sensitivity to doxorubicin-induced apoptosis. These in vitro findings were confirmed by an analysis of human HCC tissues, which revealed an inverse correlation linking miR-199a-3p and mTOR as well as a shorter time to recurrence after HCC resection in patients with lower miR-199a-3p expression. These results suggest that tactics to regulate mTOR and c-Met by elevating levels of miR-199a-3p may have therapeutic benefits in highly lethal cancers such as HCC.

[1]  Zhiming Wang,et al.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma , 2010, Medical oncology.

[2]  C. Croce,et al.  MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Dolganiuc,et al.  MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. , 2009, Alcoholism, clinical and experimental research.

[4]  M. Manns,et al.  Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage , 2009, Hepatology.

[5]  G. Tsujimoto,et al.  Identification of novel microRNA targets based on microRNA signatures in bladder cancer , 2009, International journal of cancer.

[6]  S. Giulini,et al.  MicroRNA‐23b mediates urokinase and c‐met downmodulation and a decreased migration of human hepatocellular carcinoma cells , 2009, The FEBS journal.

[7]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yi Luan,et al.  miR-199a*, a Bone Morphogenic Protein 2-responsive MicroRNA, Regulates Chondrogenesis via Direct Targeting to Smad1* , 2009, Journal of Biological Chemistry.

[9]  S. Vatner,et al.  Downregulation of MiR-199a Derepresses Hypoxia-Inducible Factor-1α and Sirtuin 1 and Recapitulates Hypoxia Preconditioning in Cardiac Myocytes , 2009, Circulation research.

[10]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[11]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[12]  R. Poon,et al.  Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. , 2009, Cancer letters.

[13]  P. Comoglio,et al.  MicroRNAs impair MET-mediated invasive growth. , 2008, Cancer research.

[14]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[15]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[16]  R. Pochampally,et al.  Human multipotent stromal cells from bone marrow and microRNA: Regulation of differentiation and leukemia inhibitory factor expression , 2008, Proceedings of the National Academy of Sciences.

[17]  C. Croce,et al.  MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[18]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[19]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[20]  J. Dufour,et al.  Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. , 2008, Journal of hepatology.

[21]  Ji Young Kim,et al.  MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2)* , 2008, Journal of Biological Chemistry.

[22]  Laura Pelletier,et al.  MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations , 2008, Hepatology.

[23]  H. Huynh,et al.  RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[24]  J. Nemunaitis,et al.  Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? , 2008, Cancer Gene Therapy.

[25]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[26]  Thomas D. Schmittgen,et al.  Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.

[27]  S. Giulini,et al.  In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. , 2007, International journal of oncology.

[28]  A. Tee,et al.  Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif* , 2007, Journal of Biological Chemistry.

[29]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[30]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[31]  Shelly C. Lu,et al.  Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density‐dependent in HepG2 cells , 2007, Journal of cellular physiology.

[32]  S. Baksh,et al.  Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance , 2007, Molecular Cancer.

[33]  J. Ajani,et al.  Molecular mechanisms in cancer: what should clinicians know? , 2005, Seminars in oncology.

[34]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[36]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[37]  L. Trusolino,et al.  Invasive growth: from development to metastasis. , 2002, The Journal of clinical investigation.

[38]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[39]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[40]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[41]  H. Lane,et al.  The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .